(2R)-2-[[9-异丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇
中文名称 | (2R)-2-[[9-异丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 |
---|---|
中文同义词 | (2R)-2-[[9-异丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇;(R)-2-((9-异丙基-6-((4-(吡啶-2-基)苄基)氨基)-9H-嘌呤-2-基)氨基)丁醇;化合物(R)-CR8 |
英文名称 | 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurinetrihydrochloride |
英文同义词 | (R)-CR8;2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurinetrihydrochloride;1-Butanol,2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]Methyl]aMino]-9H-purin-2-yl]aMino]-,(2R)-;(S)-CR8;(2R)-2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-1-butanol;R8;CR8, (R)-Isomer;(2R)-2-[[9-(1-Methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-butanol-1 |
CAS号 | 294646-77-8 |
分子式 | C24H29N7O |
分子量 | 431.53 |
EINECS号 | |
相关类别 | 有机化学 |
Mol文件 | 294646-77-8.mol |
结构式 |
(2R)-2-[[9-异丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 性质
熔点 | 98-100℃ |
---|---|
沸点 | 671.4±65.0 °C(Predicted) |
密度 | 1.27±0.1 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | 二甲基亚砜:≥10mg/mL |
酸度系数(pKa) | 14.56±0.10(Predicted) |
形态 | 粉末 |
颜色 | 米白色 |
稳定性 | 可在-20°C下的DMSO溶液保存长达1个月。 |
Cdk1/cyclin B 0.09 μM (IC 50 ) |
cdk2/cyclin A 0.072 μM (IC 50 ) |
CDK2/cyclinE 0.041 μM (IC 50 ) |
Cdk5/p25 0.11 μM (IC 50 ) |
CDK7/cyclin H 1.1 μM (IC 50 ) |
CDK9/Cyclin T 0.18 μM (IC 50 ) |
CK1δ/ε 0.4 μM (IC 50 ) |
(R)-CR8 (CR8) (0.1-100 μM; 48 hours) is a potent inducer of apoptotic cell death with an IC
50
of 0.49 μM for SH-SY5Y cell line.
(R)-CR8 (0.25-10 μM) induces a dose-dependent induction of poly-(ADP-ribose)polymerase (PARP) cleavage.
The CDK-bound form of (R)-CR8 has a solvent-exposed pyridyl moiety that induces the formation of a complex between CDK12-cyclin K and the CUL4 adaptor protein DDB1, bypassing the requirement for a substrate receptor and presenting cyclin K for ubiquitination and degradation.
Apoptosis Analysis
Cell Line: | SH-SY5Y cell line |
Concentration: | 0.1, 1, 10, 100 μM |
Incubation Time: | 24 hours |
Result: | Reduced cell survival in a dose-dependent manner. |
(R)-CR8 (5 mg/Kg; i.p.) results in a significant reduction in lesion size at 28 days in histological assessment.
Animal Model: | Adult (10 to 12 weeks old) male Sprague-Dawley rats (310 to 330 g) |
Dosage: | i.p. |
Administration: | 5 mg/Kg |
Result: | Resulted in a significant reduction in lesion size. |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-112371 | (S)-CR8 | 1 mg | 1636元 | |
2024/04/30 | HY-18340 | (2R)-2-[[9-异丙基-6-[[[4-(2-吡啶基)苯基]甲基]氨基]-9H-嘌呤-2-基]氨基]-1-丁醇 (R)-CR8 | 294646-77-8 | 5mg | 2900元 |